Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer

Urologia Internationalis

Volumn 56, Issue 3, 1996, Pages 169-173

  Wolff, J M ^a   Bores, R ^b   Jung, P K ^a   Buell, U ^b   Jakse, G ^a  

^a Departments of Urology   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Bone metastases; Cancer ofthe prostate; Prostate specific antigen; Tumor staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER SCINTISCANNING; CANCER STAGING; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

EID: 0029998925     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282834     Document Type: Article

References (21)

1. Catalona WJ, Scott WW: Carcinoma of the prostate: in Walsh PC. Gittes RF. Perlmutter AD. Stanley TA (eds): Campell's Urology, ed 5. Philadelphia, Saunders. 1986. vol 2, pp 1463-1534.
2. Whitmore WF Jr: Natural history and staging of prostate cancer. Urol Clin North Am 1984: 11:209-220.
3. McGregor B, Tulloch AGS, Quinlan MF, Lovegrove F: The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978:50:178-181.
4. O'Donoghue EPN, Constable AR, Sherwood T. Stevenson JJ. Chisholm GD: Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol 1978.50:172-178.
5. Buell U, Kleinhans E, Zorn-Bopp E, Rcuschcl W, Mucnzing W, Moser EA, Scidcrer M: A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: Concise communication. JNucI Med 1982;23:214-217.
6. Wahner HW, Brown ML: Role of bone scanning: in Sim FH (ed): Diagnosis and Management of Metastatic Bone Disease. New York. Raven Press. 1988. pp 51-67.
7. Drago JR, Badalament RA, Wientjes MG, Smith JJ, Nesbitt JA, York JP, Ashton JJ, Neff JC: Relative value of prostate-specific antigen and prostatic acid phosphate in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience. Urology 1989;34:187-192.
8. Rana A, Karamanis K, Lucal MG, Chisholm GC: Identification of metastatic disease by T category, glcason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992:69:277-281.
9. Ocstcrling JE: Prostate specific antigen: A critical assessment of the most useful tumour marker for adenocarcinoma of the prostate. J Urol 1991:145:907-923.
10. Chybowski FM, Keller JJ, Bergstrahl F.J, Oes-terling JE: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate-specific antigen is superior to all other parameters. J Urol 1991:145:313-318.
11. Oesterling JE, Martin SK, Bergstrath EJ, Lowe FC: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
12. O'Donoghue JM, Rogers E, Grimes H, McCarthy P, Corcoran M, Brcdin H, Given HF: A reappraisal of serial isotope scans in prostate cancer. Br J Radiol 1993.66:672-676.
13. Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ: Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 1994:17:432-436.
14. Brawer MK: Prostate-specific antigen: Critical issues. Urology 1994;44(suppl):9-17.1
15. Goodman CM, Cumming JA, Ritchie AWS, Chisholm GD: Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in carcinoma of the prostate. Br J Urol 1991:67:622-625.
16. Merrick MV, Ding CL, Chisholm GD, Eton RA: Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol 1985:57: 715-720.
17. dcVoogt HJ, Suciu S, Sylvester R, Pavone Ma-caluso M, Smith PH, de Pauw M: Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from 2 European organizations for research and treatment of cancer trials. J Urol 1989;41:883-888.
18. Schwartz CB, Bekirov H, Melman A: Gleason's histologic grading as clinical prognostic marker in patients with advanced prostatic carcinoma. Urology 1991;3:198-201.
19. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic pros-tatecancer based on extent of disease on initial bone scan. Cancer 1988:61:195-202.
20. Chodak GW, Vogelzang NJ, Caplan RF, Soloway M. Smith JA: Independent prognostic factors in patients w ith metastatic (stage D2) prostate cancer. JAMA 1991;265:618-621.
21. Stamey TA, Dietrick DD, Issa MM: Large, organ-confined impalpable transition zone prostate cancer, associated with metastatic levels of prostate specific antigen. J Urol 1993: 149:510-515.